Studies performed in NPC patients revealed that EBV-specific proteins such as LMP1, LMP2, and EBNA1 may serve as possible target for vaccine development and immunological modulation [53]. This evidence concerns the gene PDLIM7 and nasopharyngeal carcinoma.